Zilovertamab vedotin
MK-2140
PHASE3
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Peak Sales Est$2000M
Formulations[]
Mechanism: ROR1-directed (vedotin payload)
Expert: ROR1-directed antibody-drug conjugate with MMAE payload
Everyday: Delivers chemotherapy directly to cancer cells
Targets: ["ROR1"]
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| MCL | PHASE3 | ZILO-MCL | [] |
Notes
ROR1-directed ADC for heme malignancies. Phase 3 in MCL, CLL.
Data from Supabase · Updated 2026-03-24